Name | methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate |
Synonyms | ITE ARYL HYDROCARBON RECEPTOR LIGAND methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate Methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate 2-(1'H-INDOLE-3'-CARBONYL)-THIAZOLE-4-CARBOXYLIC ACID methyl 2-(1H-indole-3-carbonyl)-1,3-thiazole-4-carboxylate 2-(1H-INDOL-3-YLCARBONYL)-4-THIAZOLECARBOXYLIC ACID METHYL ESTER 2-(1'H-indole-37-carbonyl)-thiasole-4-carboxylic acid methyl ester 4-Thiazolecarboxylic acid, 2-(1H-indol-3-ylcarbonyl)-, methyl ester |
CAS | 448906-42-1 |
Molecular Formula | C14H10N2O3S |
Molar Mass | 286.31 |
Density | 1.427±0.06 g/cm3(Predicted) |
Melting Point | 234 - 236°C |
Boling Point | 520.4±48.0 °C(Predicted) |
Solubility | DMSO : 20 mg/ml |
Appearance | solid |
Color | Off-White to Light Yellow |
pKa | 14.38±0.30(Predicted) |
Storage Condition | 2-8°C |
Target | Ki: 3 nM (AhR) |
In vitro study | ITE is an endogenous agonist of AhR, binding directly to AHR, with a K i of 3 nM. ITE (0.03-30 mg/mL) decreases the antigen-specific T-cell proliferative responses. ITE potently inhibits human pulmonary artery endothelial (HPAECs) growth at 10 and 20 µM, but shows no effect at 0.01-5 µM. ITE does not affect cell cycle progress of HPAECs at 10 and 20 µM, or induce expression of cleaved caspase-3 protein in HPAECs at 20 µM. In addition, ITE (20 µM) elevates CYP1A1 and CYP1B1 mRNA levels and decreases the levels of AhR protein in HPAECs. |
In vivo study | ITE (200 μg, i.p.) significantly suppresses the development of experimental autoimmune uveitis (EAU) in mice. ITE reduces the proportions of cells expressing IFN-γ, IL-17, or IL-10 in mice. ITE also suppresses the secretion of inflammatory cytokines by LN cells in mice. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
Reference Show more | 1: Henry, E.C., Bemis, J.C., Henry, O., et al. A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch. Biochem. Biophys. 450(1), 67-77 (2006). 2: Yoshida, T., Katsuya, K., Oka, T., et al. Effects of AhR ligands on the production of immunoglobulins in purified mouse B cells. Biomed. Res. 33(2), 67-74 (2012). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.493 ml | 17.464 ml | 34.927 ml |
5 mM | 0.699 ml | 3.493 ml | 6.985 ml |
10 mM | 0.349 ml | 1.746 ml | 3.493 ml |
5 mM | 0.07 ml | 0.349 ml | 0.699 ml |
introduction | ITE is an aromatic hydrocarbon receptor (AhR) agonist with Ki value of 3nM,ITE acting on OVCAR-3 cell proliferation and IC50 value of 0.2nM. |
biological activity | ITE is an effective endogenous aromatic hydrocarbon receptor (AhR) agonist that can directly bind to AHR with a Ki value of 3 nM. ITE has an immunosuppressive effect. |
target | Ki: 3 nM (AhR) |
in vitro research | ITE is an endogenous agonist of AhR, binding directly to AHR, with a K I of 3 nM. ITE (0.03-30 mg/mL) decreases the antigen-specific T-cell proliferative responses. ITE potently inhibits human pulmonary order endothelial (HPAECs) growth at 10 and 20 m, but shows no effect at 0.01-5 m. ITE does not affect cell cycle progress of HPAECs at 10 and 20 m, or induce expression of cleaved caspase-3 protein in HPAECs at 20 µM. In addition, ITE (20 µM) elevates CYP1A1 and CYP1B1 mRNA levels and decreases the levels of AhR protein in HPAECs. |
in vivo research | ITE (200 μ g, I. p.) significantly suppresses the development of experimental autoimmune uveitis (EAU) in mice. ITE reduces the proportions of cells expressing IFN-γ, IL-17, or IL-10 in mice. ITE also suppresses the secretion of inflammatory cytokines by LN cells in mice. |